Jardiance

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Heart FailureChronic Kidney DiseaseType 2 Diabetes MellitusFasting ConditionsAllograft

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

1

Jardiance

Boehringer Ingelheim

Phase 3

22

Bayer Aspirin

Bayer

Preclinical

23

Brethine

Sanofi

Preclinical

14

Amidate

Pfizer

Preclinical

15

Zemplar

AbbVie

Preclinical

—6

Adriamycin

Pfizer

Preclinical

—7

Savaysa

Daiichi Sankyo

Preclinical

—8

Xifaxan

SSalix

Preclinical

29

Xylocaine

MMEDRx USA, Inc.

Preclinical

110

Tamiflu

CConrado Roberto Hoffmann Filho

Preclinical

1Show 25 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Type 2 Diabetes Mellitus3 trials

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

Completed·Boehringer Ingelheim··NCT02848833·3,368 enrolled

Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus

Completed·Boehringer Ingelheim··NCT02367131·419 enrolled

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Completed·Boehringer Ingelheim··NCT02489942·8,145 enrolled

Empagliflozin2 trials

Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting Condition

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT06180109·36 enrolled

A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together

Completed·Boehringer Ingelheim·Phase 1·NCT07035457·15 enrolled

Heart Failure2 trials

Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)

Completed·Boehringer Ingelheim··NCT05262764·1,200 enrolled

A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Jardiance® (Empagliflozin, 10mg) in Korean Patients With Chronic Heart Failure (NYHA Class II-IV)

Completed·Boehringer Ingelheim··NCT05236673·676 enrolled

Allograft1 trial

Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension

Active, not recruiting·OOdense University Hospital·Phase 4·NCT06933355·8 enrolled

Obesity1 trial

Prevention of Progression of Prediabetes, Obesity and CV Risk

Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT06446531·64 enrolled

6 more indications

Chronic Kidney Disease1 trial

Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease

Active, not recruiting·Boehringer Ingelheim··NCT06527846·1,024 enrolled

Fasting Conditions1 trial

A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions

Not yet recruiting·PPharma Nueva·Phase 1·NCT06308679·28 enrolled

Atherosclerotic Plaque1 trial

Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)

Withdrawn·UUniversity of Louisville·Phase 4·NCT06280976

Heart Failure of Reduced Ejection Fraction (HFrEF)1 trial

Non-interventional Study of the Effectiveness and Safety of Jardiance in Patients With Heart Failure (HF) of Reduced Ejection Fraction (HFrEF) Compared to Guideline-recommended Non-SGLT2i Therapy Regimens in China: A Sub-study of the Postmarketing Study of Jardiance Among Patients With Heart Failure in China

Not yet recruiting·Boehringer Ingelheim··NCT07044700·5,000 enrolled

Kidney Disease, Chronic1 trial

A Regulatory Non-interventional Study to Monitor the Safety and Efficacy of JARDIANCE® (Empagliflozin 10 mg) in Korean Patients With Chronic Kidney Disease (CKD)

Completed·Boehringer Ingelheim··NCT06287073·299 enrolled

Unspecified1 trial

Regulatory Request NIS in Korea

Completed·Boehringer Ingelheim··NCT03642717·658 enrolled

Details

Drug Info

Related News